The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase

Blood

Volumn 114, Issue 25, 2009, Pages 5146-5151

  Abbott, Lesleigh S ^a   Deevska, Mariana ^b   Fernandez, Conrad V ^a   Dix, David ^b   Price, Victoria E ^a   Wang, Hao ^a   Parker, Louise ^a   Yhap, Margaret ^a   Fitzgerald, Colleen ^b   Barnard, Dorothy R ^a   Berman, Jason N ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ASPARAGINASE; FIBRINOGEN; FRESH FROZEN PLASMA; BLOOD CLOTTING FACTOR 8; CRYOPRECIPITATE COAGULUM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTICOAGULATION; ARTICLE; BODY MASS; BRAIN HEMORRHAGE; CHILD; CONTROLLED STUDY; CRYOPRECIPITATE; FEMALE; HEALTH CARE COST; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; RISK ASSESSMENT; SCHOOL CHILD; BLEEDING; CANADA; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; COST; ECONOMICS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PLASMA; SEX DIFFERENCE; THROMBOSIS; VASCULARIZATION;

ADOLESCENT; ASPARAGINASE; BRITISH COLUMBIA; CENTRAL NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; FACTOR VIII; FEMALE; FIBRINOGEN; HEMORRHAGE; HUMANS; INFANT; MALE; NOVA SCOTIA; OUTCOME ASSESSMENT (HEALTH CARE); PLASMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; SEX FACTORS; THROMBOSIS;

EID: 73949148077     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-231084     Document Type: Article

References (34)

1. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002:489-544.
2. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999;21(1):6-12.
3. Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2006;47(3):299-304.
4. Pession A, Valsecchi MG, Masera G, et al. Longterm results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161-7167.
5. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14(12):2247-2256.
6. Haley EE, Fischer GA, Welch AD. The requirement for L-asparagine of mouse leukemia cells L5178Y in culture. Cancer Res. 1961;21:532-536.
7. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;111(3):125-131.
8. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol. 2005;129(6):803-810.
9. Lockman LA, Mastri A, Priest JR, Nesbit M. Dural venous sinus thrombosis in acute lymphoblastic leukemia. Pediatrics. 1980;66(6):943-947.
10. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97(2):508-516.
11. Ott N, Ramsay NK, Priest JR, et al. Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1988;10(3):191-195.
12. Pastore G, Miniero R, Saracco P, Lange M. Thrombosis and hemorrhage during L-asparaginase therapy. J Pediatr. 1983;102(4): 639-640.
13. Priest JR, Ramsay NK, Latchaw RE, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer. 1980;46(7):1548-1554.
14. Andrew M, Brooker L, Mitchell L. Acquired anti-thrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis. 1994; 5(suppl 1):S24-S36; discussion S59-S64.
15. Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16(2):120-126.
16. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93(5):1595-1599.
17. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007; 138(4):430-445.
18. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood. 1994;83(2):386-391.
19. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216-2222.
20. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia: results of the PAARKA study. Thromb Haemost. 2003;90(2):235-244.
21. Centers for Disease Control and Prevention. Healthy Weight: it's not a diet, it's a lifestyle. http://www.cdc.gov/healthyweight/index.html. Accessed January 15, 2009.
22. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24.
23. Mauz-Körholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83(6):840-843.
24. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia, part II: pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003;111(4-5):199-212.
25. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist. 2005;10(1):72-79.
26. Kuhle S, Lau A, Bajzar L, et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol. 2006;134(5):526-531.
27. Young G. New anticoagulants in children. Hematology Am Soc Hematol Educ Program. 2008: 245-250.
28. Nowak-Göttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101(7):2529-2533.
29. Hernández-Espinosa D, Minano A, Ordonez A, et al. Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of L-asparaginase treatment. J Thromb Haemost. 2009;7(7):1128-1133.
30. Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma: use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93(10):1488-1494.
31. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer. 2008; 113(9):2575-2596.
32. Howell DL, Ward KC, Austin HD, Young JL, Woods WG. Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia. J Clin Oncol. 2007;25(29): 4610-4615.
33. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5(3):621-623.
34. Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2001;12(5): 367-370.